Pharmacodynamic study will compare OPNT003, nasal nalmefene, with nasal naloxone in reversing the respiratory depression produced by the synthetic opioid, remifentanil Top-line data expected in the fourth quarter This trial starts at a time when deaths resulting from opioid overdose are at record

SANTA MONICA, Calif. , March 31, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, has been awarded the third and final tranche of $1.8 million from the total grant of

SANTA MONICA, Calif. , March 22, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced the appointment of Lorianne Masuoka , M.D., to its Board of Directors,

SANTA MONICA, Calif. , March 04, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the fourth quarter and year ended December 31, 2020

SANTA MONICA, Calif. , Feb. 22, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its financial results for the fourth quarter and year ended

SANTA MONICA, Calif. , Feb. 08, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT) today announced the dosing of the first patient in a confirmatory pharmacokinetic (“PK”) study for OPNT003, nasal nalmefene, for the treatment of opioid overdose.